eClinical Technology and Industy News

Biomea Fusion Releases Pre-Clinical Data with BMF-219 in Diabetes

Excerpt from the Press Release:

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that BMF-219 displayed remarkable activity in both the Zucker Diabetic Fatty (ZDF) Rat and the Streptozotocin-Induced Diabetes (STZ) animal models of type 2 diabetes.

Loss of functional Beta-cell mass is a core component of the natural history in both types of diabetes — type 1 diabetes (mediated by autoimmune dysfunction) and type 2 diabetes (mediated by metabolic dysfunction). Beta-cells are found in the pancreas and are responsible for the synthesis and secretion of insulin. Insulin is a hormone that helps the body use glucose for energy and helps control blood glucose levels. In patients with diabetes, Beta-cell mass and function are diminished, leading to insufficient insulin secretion and hyperglycemia. Menin is thought to act as a brake on Beta-cell turnover / Beta-cell growth, supporting the notion that inhibition of menin could lead to the regeneration of normal healthy Beta-cells. Notably, it has previously been shown that knocking out the gene responsible for the creation of menin (MEN1) has been observed to produce profound glycemic control in diabetic animal models. Based on these and other scientific findings, Biomea explored the potential for menin inhibition as a viable therapeutic approach to permanently halt or reverse progression of type 2 diabetes.

Focusing on the hallmark of type 2 diabetes, Beta-cell dysfunction and loss of Beta-cell mass, Biomea conducted both the ZDF and the STZ experiments to measure the potential impact of BMF-219 for the treatment of type 2 diabetes. In both models, BMF-219 was able to normalize glucose levels in the majority of animals after just two weeks of treatment. Notably, the majority of the effect was maintained despite complete washout of BMF-219. Together, Biomea believes these results indicate the clinical potential for a novel menin inhibitor as a ground-breaking treatment for type 2 diabetes. Detailed reviews of both studies will be submitted to an upcoming scientific conference. The company intends to hold a meeting with regulators this quarter to discuss plans for a Phase 1/2 study.

“While the importance of menin in Beta-cell biology has been studied for some time, the normalization of insulin and glucose levels and potential repopulation of Beta-cells with a menin inhibitor in two distinct models is very unusual and noteworthy,” said Rohit Kulkarni MD, PhD, Senior Investigator and Margaret A Congleton Professor; Section Head, Islet Cell and Regenerative Biology; and Professor of Medicine, Harvard Medical School. “I am looking forward to engaging with the Biomea team to support the clinical development of this exciting compound for the treatment of diabetes.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives